We are very thrilled to support the Real World Data study entitled “Non-Interventional, National Study of Real-World Evidence in Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients Treated with Palbociclib During a 2.5 Years Follow-Up Period.”
The study initiated by the investigator, started a few months ago, at national level, in 6 Oncology research sites in Romania, located in Timisoara, Oradea, Bucuresti, Cluj Napoca, Iasi and Craiova, under the coordination of Dr. Cristina Oprean – Oncologist from OncoHelp Oncology Center Timișoara.
This retrospective, multicentric study will investigate the safety and efficacy profile of a Cyclin-dependent kinase (CDK) 4/6 inhibitor in the real-world setting of clinical practice in patients with HR+/HER2− advanced or metastatic breast cancer.
RWD studies bring valuable information related to the drug safety and efficacy profiling and a broader understanding of the practice pattern and outcomes of the studied drug.